Arkuda is comprised of passionate and experienced team members who are dedicated to improving the lives of people affected by neurodegenerative disease. Armed with deep expertise in biology and the ability to understand the root cause of disease, we are discovering medicines with the potential to positively change the trajectory of neurodegeneration.

Gerhard Koenig

"Losing the quintessential essence of what makes us human is a devastating verdict for people and caregivers alike. To be able to prevent or stop disease progression is Arkuda’s core mission."


Co-founder, President and CEO

Duane Burnett

"I’ve had friends and family affected by neurodegeneration - it’s long been a personal goal of mine to create drugs that can change the course of disease."

Duane Burnett, PhD,

Co-founder, Senior Vice President, Discovery

Serena Hung

"As a neurologist, I always wished I had something to offer my patients with neurodegenerative diseases to slow disease progression."

Serena Hung, MD,

Head of Clinical Development

Andy Hu

"I’ve had loved ones affected by neurodegeneration and experienced firsthand the devastation caused to patients and those close to them."

Andy Hu, MD,

Chief Business Officer

Anna-Maria Alves,

Associate Scientist

Jean Francois Blain

Jean-François Blain, PhD,

Vice President, Neurobiology

Morgan Brand,

Associate Scientist

Jerusha Thedsanamoorthy

Jerusha Brendel,

Research Associate

Angela Chen

Angela Chen,


Christopher Holler

Christopher Holler, PhD,

Senior Scientist

Raymond Hurst, PhD,

Vice President, Pharmacology

Jim Lanter

Jim Lanter, PhD,

Vice President, Medicinal Chemistry

Stephanie McTighe, PhD,

Associate Director, Pharmacology

Denise Peters,

Accounting Controller

John Ross,

Senior Toxicologist

Hillary Van Voorhies,

Associate Director, R&D Program Management

Mary Wozniak

Mary Wozniak,

Research Associate